Version history

{
  "description": "The domain expert identified p-tau217 as the most clinically viable threshold marker, but its validation as a stopping rule requires prospective studies. This directly addresses the clinical practice gap identified in the source paper.\n\nSource: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab)",
  "domain": "neurodegeneration",
  "status": "investigating",
  "priority_score": 0.88,
  "importance_score": 0.82,
  "tractability_score": 0.75,
  "novelty_score": 0.65,
  "composite_score": 0.6441,
  "source": "debate:sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142",
  "resolution_criteria": "Resolution requires: (1) head-to-head comparison of CSF p-tau217 normalization vs amyloid PET (Pib/Pirlo) as surrogate endpoints in Phase 3 trials (n≥300 per arm) showing whether p-tau217 change predicts clinical outcomes with AUC ≥0.80; (2) definition of cessation threshold (% change from baseline) with ≥90% specificity for amyloid clearance; (3) regulatory validation study using historical data from TRAILBLAZER or DIAN-TU trials. Single-arm studies are insufficient.",
  "market_price": 0.44
}